Literature DB >> 12430929

Important features of myelodysplastic syndrome.

Wolf K Hofmann1, H Phillip Koeffler.   

Abstract

Myelodysplastic syndromes (MDS) are characterized by peripheral cytopenias in combination with a hyperplastic bone marrow. During the last 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndromes. The classification according to the World Health Organization (WHO) includes mainly morphological criteria and is supplemented by the International Prognostic Scoring System (IPSS) which takes cytogenetical changes into consideration when determining the prognosis of MDS. Also MDS after radiotherapy, chemotherapy or chemical exposure must be distinguished from primary MDS. The underlying mechanisms in primary MDS have not yet been established but it is a multistep alteration to the hematopoietic stem cells that include genes involved in cell cycle control, mitotic checkpoints as well as growth factor receptors, secondary signal proteins and transcription factors which gives the cell a growth advantage over its normal counterpart.

Entities:  

Mesh:

Year:  2002        PMID: 12430929     DOI: 10.1007/bf03165121

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  53 in total

1.  Pure red cell aplasia associated with myelodysplastic syndromes.

Authors:  S Park; A Merlat; M Guesnu; F Picard; F Viguié; D Vassilieff; F Dreyfus
Journal:  Leukemia       Date:  2000-09       Impact factor: 11.528

2.  Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius.

Authors:  P E Neiman; A Ruddell; C Jasoni; G Loring; S J Thomas; K A Brandvold; J Burnside; J Delrow
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  Histopathology       Date:  2000-01       Impact factor: 5.087

Review 4.  Ras and myelodysplasia: lessons from the last decade.

Authors:  J Parker; G J Mufti
Journal:  Semin Hematol       Date:  1996-07       Impact factor: 3.851

Review 5.  Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes.

Authors:  J E Parker; G J Mufti
Journal:  Br J Haematol       Date:  1998-05       Impact factor: 6.998

6.  Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants.

Authors:  J DeRisi; B van den Hazel; P Marc; E Balzi; P Brown; C Jacq; A Goffeau
Journal:  FEBS Lett       Date:  2000-03-24       Impact factor: 4.124

7.  The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q.

Authors:  A Borkhardt; S Bojesen; O A Haas; U Fuchs; D Bartelheimer; I F Loncarevic; R M Bohle; J Harbott; R Repp; U Jaeger; S Viehmann; T Henn; P Korth; D Scharr; F Lampert
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

8.  Smoking and myelodysplastic syndromes.

Authors:  J Björk; M Albin; N Mauritzson; U Strömberg; B Johansson; L Hagmar
Journal:  Epidemiology       Date:  2000-05       Impact factor: 4.822

9.  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes.

Authors:  T Uchida; T Kinoshita; H Nagai; Y Nakahara; H Saito; T Hotta; T Murate
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

10.  Infrequent microsatellite instability during the evolution of myelodysplastic syndrome to acute myelocytic leukemia.

Authors:  T Tasak; S Lee; S Spira; S Takeuchi; Y Hatta; M Nagai; J Takahara; H P Koeffler
Journal:  Leuk Res       Date:  1996-02       Impact factor: 3.156

View more
  1 in total

Review 1.  Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.

Authors:  Peng Liu; Zhong Chao Han
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.319

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.